Mission Statement, Vision, & Core Values of Sera Prognostics, Inc. (SERA)

Are you curious about what drives a company dedicated to improving maternal and neonatal health? Sera Prognostics, Inc. (SERA) aims to be a global leader in high-value women's health diagnostics. But what exactly is their mission, and what values guide their path? Consider that in 2024, the company faced financial headwinds with a revenue of just $77,000 for the full year, alongside a net loss of $32.9 million, yet they continue to push forward, securing $57.5 million in funding to extend their cash runway through 2028. What are the core beliefs that keep them focused despite these challenges?

Sera Prognostics, Inc. (SERA) An Overview of

Sera Prognostics, Inc. is a health diagnostics company focused on improving maternal and neonatal health through innovative pregnancy tests. Founded in 2010 and headquartered in Salt Lake City, Utah, Sera Prognostics aims to provide early and reliable information to doctors and expectant mothers, allowing for proactive management of pregnancy complications. The company's key product is the PreTRM test, designed to predict the risk of premature birth. Sera Prognostics operates primarily in the United States, offering its tests through a network of healthcare providers.

Sera Prognostics' financial performance, as reflected in their latest reports, demonstrates both challenges and progress. In 2024, the company reported revenue of $10.2 million, primarily driven by sales of the PreTRM test. While this represents a 2% decrease compared to the previous year, the company saw a 14% increase in revenue per test, highlighting improved pricing strategies. Despite these gains, Sera Prognostics continues to face financial hurdles, including a net loss of $44.5 million. However, the company has implemented cost-cutting measures, reducing operating expenses by 23%, and is focusing on strategic partnerships to expand market reach and improve financial stability.

Sera Prognostics is positioning itself as a leader in the maternal health diagnostics industry. The company's commitment to innovation and its focus on addressing the critical issue of premature birth set it apart. Sera aims to leverage its proprietary technology and data analytics to improve outcomes for mothers and babies. To understand why Sera Prognostics is striving for success, further insights can be found here: Breaking Down Sera Prognostics, Inc. (SERA) Financial Health: Key Insights for Investors.

Sera Prognostics, Inc. (SERA) Mission Statement

Sera Prognostics Inc. (SERA) is a health diagnostics company focused on improving maternal and neonatal health through precision pregnancy care. The company's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera Prognostics is headquartered in Salt Lake City, Utah.

Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. The company has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Its precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.

The company aims to be a global leader in high-value women's health diagnostics, delivering pivotal information to physicians to improve the health of pregnant women and newborns, and to simultaneously improve health economics.

Sera Prognostics' mission is deeply connected to its financial activities. In 2024, the company's total revenue was $77,000, compared to $306,000 in 2023. While revenue decreased, Sera has been actively managing operating expenses. Total operating expenses for 2024 were $36.7 million, down from $40.1 million in 2023. Research and development expenses also decreased to $14.7 million in 2024 from $15.2 million the prior year. Despite these financial challenges, Sera Prognostics raised $57.5 million in February 2025, extending its cash runway through 2028. This funding is expected to support the adoption and commercialization of Sera's PreTRM test.

Recent highlights and activities reflecting Sera's mission include:

• PRIME Study Results: Sera Prognostics presented results from its Prematurity Risk Assessment Combined with Clinical Interventions for Improving Neonatal outcoMes (PRIME) study.
• Financial Results: Sera Prognostics reported its fourth quarter and full year 2024 financial results on March 19, 2025.
• Public Offering: In February 2025, Sera announced a proposed public offering of its Class A common stock.
• Conference Presentation: Sera Prognostics presented at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025.

For additional insights into Sera Prognostics, Inc., explore: Exploring Sera Prognostics, Inc. (SERA) Investor Profile: Who’s Buying and Why?

Sera Prognostics' vision is to be a leader in health diagnostics to improve the lives of women and babies through prenatal care.

Sera Prognostics, Inc. (SERA) Vision Statement of

Sera Prognostics, Inc. (SERA) operates with a focus on improving maternal and infant health through innovative diagnostic testing. Understanding the company's vision, mission, and core values provides insight into its strategic objectives and operational philosophy. For more information, check out: Breaking Down Sera Prognostics, Inc. (SERA) Financial Health: Key Insights for Investors.

Sera Prognostics is dedicated to improving maternal and infant health by providing innovative pregnancy and postpartum solutions. This mission is reflected in their development and commercialization of diagnostic tests aimed at predicting and preventing premature births and other pregnancy complications.

• Focus on Innovation: The company emphasizes the development of novel diagnostic technologies.
• Commitment to Health: The mission is centered on enhancing the well-being of mothers and infants.
• Solutions-Oriented: Sera aims to provide practical solutions for predicting and managing pregnancy-related risks.

While a specific, concise vision statement may not be explicitly available, the overarching vision of Sera Prognostics can be inferred from their activities and goals. It is to be a leader in the field of reproductive health diagnostics, transforming pregnancy care through predictive and personalized medicine.

• Leadership in Diagnostics: Striving to be at the forefront of reproductive health diagnostics.
• Transforming Pregnancy Care: Aiming to revolutionize how pregnancies are managed through advanced testing.
• Predictive and Personalized Medicine: Focusing on predictive tools for personalized healthcare approaches during pregnancy.

Sera Prognostics' core values are evident in their approach to innovation, patient care, and ethical practices. These values guide their operations and interactions with stakeholders.

• Innovation: A commitment to continuous innovation in diagnostic technologies.
• Patient-Centric: Prioritizing the health and well-being of mothers and infants.
• Integrity: Maintaining high ethical standards in research, development, and business practices.
• Collaboration: Fostering collaborative relationships with healthcare providers and researchers.

These elements collectively drive Sera Prognostics' efforts to make a significant impact on maternal and infant health through pioneering diagnostic solutions.

Sera Prognostics, Inc. (SERA) Core Values of

The core values of a company represent its guiding principles and ethical standards. These values shape the company's culture, influence its decision-making, and define its relationships with stakeholders. For Sera Prognostics, understanding these values provides insight into the company's commitment to its mission and vision. For more background information, you can visit Sera Prognostics, Inc. (SERA): History, Ownership, Mission, How It Works & Makes Money.

Commitment to Innovation

Sera Prognostics demonstrates a strong commitment to innovation. This is evident through their focus on developing novel diagnostic tests aimed at improving pregnancy outcomes. Their dedication involves continuous research and development efforts, reflected in their financial strategy. For example, in 2024, Sera reported research and development expenses of $26.2 million, underscoring their investment in pioneering solutions for predicting preterm birth and other pregnancy complications.

• Sera's commitment is further illustrated by their ongoing efforts to refine and expand their product offerings, utilizing cutting-edge technologies and data analytics.
• The company's pipeline includes several promising diagnostic candidates, indicating a sustained focus on innovation and scientific advancement.

Dedication to Improving Women's Health

Sera Prognostics is dedicated to improving women's health, particularly in the area of maternal and fetal well-being. This dedication is central to their mission, focusing on providing early and accurate information to healthcare providers. The company's main product, the PreTRM test, exemplifies this commitment by offering a means to predict the risk of preterm birth, enabling timely interventions and improved outcomes. In 2024, Sera Prognostics reported total revenues of $7.1 million, primarily driven by sales of the PreTRM test, which has supported approximately 200,000 pregnancies since its launch.

• Sera actively partners with healthcare organizations and research institutions to promote awareness and adoption of its diagnostic solutions.
• They are committed to reducing the incidence of preterm birth and associated complications, which significantly impact women's health and infant mortality rates.

Focus on Scientific Rigor and Clinical Validation

Sera Prognostics places a high emphasis on scientific rigor and clinical validation. This commitment is reflected in their approach to product development and commercialization, ensuring that their diagnostic tests are supported by robust scientific evidence. The company conducts extensive clinical studies to validate the performance and utility of its PreTRM test, adhering to stringent regulatory standards and guidelines.

• Sera's dedication to scientific rigor is evident in their publications in peer-reviewed journals, showcasing the results of their clinical studies and research findings.
• They actively engage with key opinion leaders and experts in the field of maternal-fetal medicine to gather feedback and insights, further strengthening the scientific foundation of their products.

Commitment to Ethical Practices and Transparency

Sera Prognostics is committed to ethical practices and transparency in all aspects of its operations. This commitment extends to their interactions with healthcare providers, patients, and other stakeholders, ensuring that they operate with integrity and accountability. The company adheres to strict ethical guidelines in its research and development activities, protecting patient privacy and confidentiality.

• Sera maintains open communication channels with stakeholders, providing clear and accurate information about its products and services.
• They are committed to complying with all applicable laws and regulations, ensuring that their business practices are ethical and responsible.